Pivicil200 mg

Pivicil is a beta-lactam antibiotic (amidinopenicillin class) indicated for the treatment of specific bacterial infections. Its indications, classified by strength of evidence, are as follows:

Established / Approved Use

• Uncomplicated lower urinary tract infection (acute cystitis): Pivicil is indicated for the treatment of uncomplicated urinary tract infections (acute cystitis) in adult women caused by susceptible strains of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus. It is not indicated for pyelonephritis or complicated UTI.

Guideline-Supported Use

• Several international UTI treatment guidelines list Pivicil as a first-line or alternative first-line option for uncomplicated cystitis in non-pregnant and, in some national guidelines, pregnant women, owing to its narrow-spectrum activity against common uropathogens and its distinguishing mechanism of action (preferential binding to penicillin-binding protein 2, PBP2) compared with typical penicillins.

Not Established

• Safety and efficacy have not been established for pyelonephritis, complicated UTI, use in men, or use in patients under 18 years of age; Pivicil should not be used for these indications outside specific physician direction.

Pivicil should only be used for infections proven or strongly suspected to be caused by susceptible bacteria, as prescribed by a physician.

Each tablet contains Pivmecillinam (as pivmecillinam hydrochloride) as the active pharmaceutical ingredient. Pivmecillinam is a prodrug ester of mecillinam (amdinocillin), a semi-synthetic amidinopenicillin. Strength and excipients vary by manufacturer and formulation; refer to the specific product label for exact composition.

Pivicil is an orally-administered prodrug of mecillinam, a beta-lactam antibiotic belonging to the amidinopenicillin subclass of penicillins. After oral absorption, Pivicil is rapidly hydrolyzed by esterases in the intestinal wall and blood to release active mecillinam, along with formaldehyde and pivalic acid as inactive byproducts. Unlike most penicillins, mecillinam has predominant activity against gram-negative bacteria and a distinct mechanism of bacterial cell wall inhibition, making Pivicil particularly useful for uncomplicated urinary tract infections caused by susceptible gram-negative uropathogens such as E. coli.

Pivicil belongs to the beta-lactam antibiotic class, specifically the amidinopenicillin (mecillinam ester/prodrug) subclass of penicillins.

Pivmecillinam is an inactive ester prodrug that is hydrolyzed after absorption to its active form, mecillinam. Mecillinam exerts bactericidal activity by binding with high affinity and selectivity to penicillin-binding protein 2 (PBP2) in the bacterial cell wall of susceptible gram-negative organisms. This differs from most other beta-lactams (including aminopenicillins and cephalosporins), which primarily target PBP1 and PBP3. Inhibition of PBP2 disrupts the rod shape of the bacterial cell, causing the organism to become a large, osmotically fragile spheroplast that eventually lyses and dies. This distinct target site accounts for the drug's characteristic activity against many gram-negative uropathogens, including some strains resistant to other beta-lactams, and for a low propensity to select for resistance during short-course cystitis therapy.

Pharmacokinetics: After oral administration, Pivmecillinam is well absorbed and rapidly and almost completely hydrolyzed to mecillinam in the intestinal mucosa and plasma. Mecillinam is widely distributed, achieves high concentrations in urine, is minimally protein bound, and is eliminated primarily unchanged by renal excretion (glomerular filtration and tubular secretion). The elimination half-life is approximately 1 to 2 hours in patients with normal renal function.

Pivicil tablets are for oral use only. Swallow the tablet whole with a glass of water; do not crush or chew unless directed by a physician. It may be taken with or without food. Doses should be spaced evenly through the day (approximately every 8 hours) to maintain effective drug levels, and the full course should be completed even if symptoms resolve before the course ends.

The following clinically significant drug interactions have been identified with Pivicil (mecillinam):

• Probenecid: Probenecid competitively inhibits renal tubular secretion of mecillinam, increasing and prolonging its plasma concentrations. This combination is sometimes used deliberately under medical supervision but should not be combined without physician guidance.
• Valproic acid / sodium valproate: Co-administration may increase the risk and severity of carnitine depletion associated with the pivalic acid component of Pivicil, since valproate itself can also reduce carnitine levels. This combination should be used with caution and only under close medical supervision.
• Warfarin and other oral anticoagulants: Like other antibiotics, Pivicil may alter gut flora responsible for vitamin K production, potentially potentiating the anticoagulant effect of warfarin. Monitor INR more closely if these are co-administered.
• Oral contraceptives: As with other antibiotics, there is a theoretical risk that Pivicil may reduce the efficacy of estrogen-containing oral contraceptives by altering gut flora involved in enterohepatic recirculation. An additional non-hormonal (barrier) method of contraception is advisable during treatment and for a short period afterward.

Inform your physician or pharmacist of all medicines, supplements, and herbal products you are taking before starting Pivicil.

Most patients tolerate Pivicil well. Reported adverse effects include:

Common

• Nausea
• Diarrhea
• Headache
• Vulvovaginal candidiasis (vaginal yeast infection)

Less Common / Uncommon

• Skin rash
• Hypersensitivity reactions (see Precautions and Warnings)
• Abdominal discomfort, vomiting

Rare but Clinically Important

• Carnitine deficiency: With prolonged or frequently repeated courses of Pivicil, depletion of body carnitine stores (from the pivalic acid component) can occur, rarely producing symptoms of muscle weakness or metabolic disturbance. This risk is low with typical short-course (3-7 day) UTI treatment but rises with extended or recurrent use.
• Severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) — rare, see Precautions and Warnings.
• Clostridioides difficile-associated diarrhea, ranging from mild to severe colitis.

Contact your physician if you experience severe or persistent side effects while taking Pivicil.

Pregnancy: Data on the use of Pivicil in pregnant women are limited. As a beta-lactam/penicillin-related antibiotic, it is generally considered among the lower-risk antibiotic options, and some international guidelines include it as an option for uncomplicated UTI in pregnancy; however, this is not an approved use in all markets. Pivicil should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus, and only as prescribed by a physician.

Lactation: Mecillinam is excreted in small amounts in human breast milk. Caution is advised; consult a physician to weigh the benefits of treatment against the theoretical risk of effects on the breastfed infant (such as diarrhea or allergic sensitization) before use during breastfeeding.

The following precautions apply to the use of Pivicil:

• Hypersensitivity reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported with penicillin-class antibiotics, including Pivicil. Discontinue immediately and seek emergency care if signs of a severe allergic reaction occur (swelling of the face/throat, difficulty breathing, severe rash).
• Serious skin reactions: Rare cases of Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported. Discontinue Pivicil at the first sign of a severe skin reaction.
• Carnitine depletion: Prolonged or repeated courses of Pivicil can deplete body carnitine stores because of its pivalic acid component. Avoid prolonged or frequently repeated use, particularly in patients with pre-existing carnitine deficiency, poor nutritional status, or those on concurrent valproic acid therapy (see Contraindications and Interactions).
• Clostridioides difficile-associated diarrhea: As with nearly all antibacterial agents, Pivicil may lead to overgrowth of C. difficile, causing diarrhea ranging from mild to fatal colitis. Evaluate if diarrhea occurs during or after treatment.
• Development of drug-resistant bacteria: Use of Pivicil in the absence of a proven or strongly suspected susceptible bacterial infection is unlikely to provide benefit and increases the risk of resistant organisms developing.
• Antibiotic stewardship: Take Pivicil exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.

Limited data are available on overdose with Pivicil. Expected effects of overdose are largely extensions of known side effects, such as nausea, vomiting, and diarrhea, and theoretically increased risk of carnitine-related effects with very high or repeated overdoses. In case of a suspected overdose of Pivicil, seek immediate medical attention or contact a poison control center/emergency services. Do not attempt specific home treatment; management is supportive and symptomatic, guided by a physician.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Safety and efficacy of Pivicil have not been established in patients under 18 years of age. Pivicil is not recommended for use in children pending further clinical data.

Geriatric Use

Clinical experience in elderly patients is limited. Elderly patients, particularly those with reduced renal function, should be monitored, and dose/interval adjustment considered by the physician (see Dosage and Administration - Renal Impairment).

Renal Impairment

Use with caution; consider extended dosing intervals in severe renal impairment (see Dosage and Administration).

Hepatic Impairment

Pivicil is contraindicated in patients with primary or secondary carnitine deficiency and should be used with caution in severe hepatic impairment given the rare risk of hepatic/carnitine-related effects with prolonged use.

Male Patients

Safety and efficacy have not been established in men; Pivicil is indicated for use in adult women only for the approved uncomplicated cystitis indication.

The typical duration of treatment with Pivicil for uncomplicated acute cystitis is 3 to 7 days, as determined by the prescribing physician based on clinical response and severity. The full prescribed course should always be completed, even if symptoms improve earlier, to reduce the risk of relapse and antibiotic resistance. Prolonged or repeated courses beyond what is prescribed should be avoided due to the risk of carnitine depletion (see Precautions and Warnings).

Pivmecillinam is classified as a beta-lactam antibiotic, in the amidinopenicillin subclass of penicillins (a mecillinam ester prodrug).

Pivmecillinam is hydrolyzed after absorption to active mecillinam, which selectively binds to penicillin-binding protein 2 (PBP2) on susceptible gram-negative bacteria. This inhibits normal cell wall elongation, causing the bacteria to lose their characteristic rod shape and become fragile, rounded spheroplasts that lyse and die. This mechanism differs from that of typical penicillins, which mainly act on PBP1 and PBP3, giving Pivmecillinam a distinct spectrum concentrated against gram-negative uropathogens.

The safety and efficacy of Pivicil have not been established in pediatric patients (under 18 years of age). Pivicil should not be used in children outside of specific physician direction based on individualized clinical judgment, given the lack of established pediatric dosing and safety data.